NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vincere Biosciences

Vincere Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vincerebio.com/

Last Round

Grant

Nov 18, 2025

Total Funding Raised

$7.25M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vincere Biosciences is a biotechnology company that develops small molecule therapeutics to treat age-related diseases, such as Parkinson's, by enhancing mitochondrial quality control.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

drug discoverysmall-molecule therapeuticsmitochondrial dysfunctioncomputational biologyUSP30 inhibitorParkinson's diseasemitophagyin-silico drug discoveryAI drug discoverybiotech R&Dneurodegenerative diseasevirtual celltechbiosmall business innovation researchSBIRdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vincere Biosciences Comparables

Compare Vincere Biosciences with similar companies based on industry and business-model similarity.

Vincere Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Vincere Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 18, 2025
StrategicMay 22, 2025
GrantSep 25, 2023
StrategicJun 12, 2023
GrantJun 27, 2022
Grant
Apr 13, 2020

Key People

Founding team and executive leadership

Spring Behrouz

CEO

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    Secured $5M in grant funding.

  • Jun 27, 2022

    $300K grant from the National Institute on Aging.

Vincere Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vincere Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vincere Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range11
Year Founded2018
Last FundingNov 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.